23 Feb Avectas
Justin McCue, Ph.D., Chief Technology Officer
April 12 | 2:45pm | Dark Horse Consulting Ballroom
Kildare, Ireland
(Private)
Avectas is a cell engineering company that has pioneered – SOLUPORE® – a proprietary simple, highly effective automated transfection system to enable efficient and safe genetic modification, accelerating the manufacture of cells for the next generation of cell therapies. The company is partnering its cGMP aligned SOLUPORE® clinical-grade system with cell therapy companies to address emerging cell delivery challenges associated with multiple cell modifications, and engineering of cells that are limited or fragile. SOLUPORE® has strong intellectual property protection through granted and pending patents, including in the U.S. and Europe. Avectas is a private, international company with research facilities in Dublin, as well as an office in Cambridge, MA in the U.S. It has over 30 employees and is led by a team of highly experienced pharmaceutical executives who are supported by a world-class Scientific Advisory Board of cancer cell therapy experts. The company has raised over $40 million USD to date.
